MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The present study was designed to characterize transduction of non-human primate brain and spinal cord with AAV5 viral vector after parenchymal delivery. AAV5-CAG-GFP (1 × 10 13 vector genomes per milliliter (vg ml −1 )) was bilaterally infused either into putamen, thalamus or with the combination left putamen and right thalamus. Robust expression of GFP was seen throughout infusion sites and also in other distal nuclei. Interestingly, thalamic infusion of AAV5 resulted in the transduction of the entire corticospinal axis, indicating transport of AAV5 over long distances. Regardless of site of injection, AAV5 transduced both neurons and astrocytes equally. Our data demonstrate that AAV5 is a very powerful vector for the central nervous system and has potential for treatment of a wide range of neurological pathologies with cortical, subcortical and/or spinal cord affection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Davidson, B. L., Stein, C. S., Heth, J. A., Martins, I., Kotin, R. M., Derksen, T. A., Zabner, J., Ghodsi, A., & Chiorini, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3428 · Cited by 531
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Adeno-Associated Virus Serotype 9 Transduction in the Central Nervous System of Nonhuman Primates
Samaranch, L., Salegio, E. A., San Sebastian, W., Kells, A. P., Foust, K. D., Bringas, J. R., Lamarre, C., Forsayeth, J., Kaspar, B. K., & Bankiewicz, K. S. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.200 · Cited by 299
Self-citationAxonal transport of adeno-associated viral vectors is serotype-dependent
Salegio, E. A., Samaranch, L., Kells, A. P., Mittermeyer, G., San Sebastian, W., Zhou, S., Beyer, J., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2012.27 · Cited by 156
Self-citationCiesielska, A., Hadaczek, P., Mittermeyer, G., Zhou, S., Wright, J. F., Bankiewicz, K. S., & Forsayeth, J. (2013) · Molecular Therapy · doi:10.1038/mt.2012.167 · Cited by 108
Self-citationUnzu, C., Hervás-Stubbs, S., Sampedro, A., Mauleón, I., Mancheño, U., Alfaro, C., de Salamanca, R. E., Benito, A., Beattie, S. G., Petry, H., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-122 · Cited by 69
Self-citationAdeno-associated virus type 6 is retrogradely transported in the non-human primate brain
San Sebastian, W., Samaranch, L., Heller, G., Kells, A. P., Bringas, J., Pivirotto, P., Forsayeth, J., & Bankiewicz, K. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.48 · Cited by 62
Self-citationMerienne, N., Douce, J. L., Faivre, E., Déglon, N., & Bonvento, G. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00106 · Cited by 58
Cited by
Noncoding RNA therapeutics—Challenges and potential solutions
Winkle, M., El-Daly, S. M., Fabbri, M., & Calin, G. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00219-z · Cited by 1,551
Emerging concepts of miRNA therapeutics: from cells to clinic
Diener, C., Keller, A., & Meese, E. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.02.006 · Cited by 971
Trials and Tribulations of MicroRNA Therapeutics
Seyhan, A. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031469 · Cited by 381
Therapies targeting DNA and RNA in Huntington's disease
Wild, E. J., & Tabrizi, S. J. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30280-6 · Cited by 298
Gene Therapy for Neurodegenerative Diseases
Sudhakar, V., & Richardson, R. M. (2019) · Neurotherapeutics · doi:10.1007/s13311-018-00694-0 · Cited by 212
Self-citationGene therapy for neurodegenerative disorders: advances, insights and prospects
Chen, W., Hu, Y., & Ju, D. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.015 · Cited by 187
Evers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168
Self-citationOhno, K., Samaranch, L., Hadaczek, P., Bringas, J. R., Allen, P. C., Sudhakar, V., Stockinger, D. E., Snieckus, C., Campagna, M. V., San Sebastian, W., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.001 · Cited by 85
Self-citationMir-17∼92 Confers Motor Neuron Subtype Differential Resistance to ALS-Associated Degeneration
Tung, Y.-T., Peng, K.-C., Chen, Y.-C., Yen, Y.-P., Chang, M., Thams, S., & Chen, J.-A. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.04.016 · Cited by 53
Fajardo-Serrano, A., Rico, A. J., Roda, E., Honrubia, A., Arrieta, S., Ariznabarreta, G., Chocarro, J., Lorenzo-Ramos, E., Pejenaute, A., Vázquez, A., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126389 · Cited by 32
Metadata
- Authors
- Samaranch, L., Blits, B., San Sebastian, W., Hadaczek, P., Bringas, J., Sudhakar, V, Macayan, M., Pivirotto, P. J., Petry, H., & Bankiewicz, K. S.
- Venue
- Gene Therapy
- Published
- 2017-03-16
- Volume
- 24
- Issue
- 4
- Pages
- 253-261
- ISSN
- 0969-7128 (ISSN-L)
- 1476-5462
- OpenAlex
- W2597277209
- Cited by
- 80
- References
- 9
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.